Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Rahul Naskar has years of experience writing news and features related to Android, phones, and apps. Outside the tech world, he follows global events and developments shaping the world of geopolitics.

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

With finals over and done with, I’ve been spending my extra free time doom-scrolling on Instagram Reels. Now that I have more time on my hands, I’ve noticed just how many additions Reels has had in ...

The LinkedIn algorithm can feel like a mysterious gatekeeper, deciding which posts reach only a few connections and which break free into wider feeds. For professionals, creators, and brands, ...

In 2025, the Instagram algorithm has become more advanced than ever, using artificial intelligence and machine learning to decide what content users see in their Feeds, Reels, Stories, Explore pages, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

In my previous article, "Agentic, Generative and Predictive: How the AI Orchestra Works in Harmony," I looked into the roles different AI capabilities can perform to harmonize customer experiences and ...

In this tutorial, we will discover how to harness the power of an advanced AI Agent, augmented with both Python execution and result-validation capabilities, to tackle complex computational tasks. By ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...